Foundation Medicine Inc (NASDAQ:FMI) SVP Robert W. Hesslein sold 6,231 shares of the firm’s stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $31.67, for a total value of $197,335.77. Following the completion of the sale, the senior vice president now directly owns 104,305 shares in the company, valued at approximately $3,303,339.35. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Robert W. Hesslein also recently made the following trade(s):
- On Wednesday, January 4th, Robert W. Hesslein sold 4,682 shares of Foundation Medicine stock. The stock was sold at an average price of $17.74, for a total value of $83,058.68.
Shares of Foundation Medicine Inc (NASDAQ:FMI) remained flat at $32.45 during mid-day trading on Monday. The company had a trading volume of 168,079 shares. The firm’s market cap is $1.15 billion. The company’s 50-day moving average is $25.80 and its 200 day moving average is $22.43. Foundation Medicine Inc has a 1-year low of $15.10 and a 1-year high of $35.30.
Foundation Medicine (NASDAQ:FMI) last posted its quarterly earnings data on Wednesday, February 22nd. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.06. Foundation Medicine had a negative return on equity of 42.21% and a negative net margin of 84.67%. The business had revenue of $28.80 million for the quarter, compared to analyst estimates of $29.23 million. During the same period in the prior year, the firm posted ($0.55) EPS. Foundation Medicine’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities research analysts forecast that Foundation Medicine Inc will post ($3.95) earnings per share for the current fiscal year.
var userip;Your IP Address: document.write(userip);
Several institutional investors have recently bought and sold shares of the company. Commerzbank Aktiengesellschaft FI boosted its position in Foundation Medicine by 0.8% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 11,492 shares of the company’s stock valued at $203,000 after buying an additional 93 shares in the last quarter. Royal Bank of Canada boosted its position in Foundation Medicine by 0.4% in the second quarter. Royal Bank of Canada now owns 25,676 shares of the company’s stock valued at $479,000 after buying an additional 100 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its position in shares of Foundation Medicine by 5.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,898 shares of the company’s stock valued at $193,000 after buying an additional 583 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Foundation Medicine by 0.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 122,863 shares of the company’s stock valued at $2,869,000 after buying an additional 599 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Foundation Medicine by 24.7% in the third quarter. Wells Fargo & Company MN now owns 5,360 shares of the company’s stock valued at $125,000 after buying an additional 1,062 shares in the last quarter. 31.44% of the stock is owned by institutional investors and hedge funds.
Several brokerages recently issued reports on FMI. Zacks Investment Research raised Foundation Medicine from a “sell” rating to a “hold” rating in a report on Thursday, March 9th. Janney Montgomery Scott raised Foundation Medicine from a “sell” rating to a “neutral” rating and set a $31.00 price target on the stock in a report on Tuesday, March 7th. Six investment analysts have rated the stock with a hold rating, The company has a consensus rating of “Hold” and an average price target of $27.33.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies.
Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.